1. Graham A, Adeloye D, Grant
L, Theodoratou E, Campbell H.
Estimating the incidence of colorectal
cancer in Sub-Saharan Africa: A
systematic analysis. J Glob Health.
2012;2(2).
2. Torre LA, Bray F, Siegel RL, Ferlay
J, Lortet-Tieulent J JA, Al E. Global
cancer statistics. CA Cancer J Clin.
2012;65:87–108.
3. van der Pool AE, Damhuis RA,
Ijzermans JN, de Wilt JH, Eggermont
AM, Kranse R VC. Trends in
incidence, treatment and survival
of patients with stage IV colorectal
cancer: a population-based series.
Color Dis. 2012;14(1):56–61.
4. Abdalla EK, Hicks ME VJ. Review
Portal vein embolization: rationale,
technique and future prospects. Br J
Surg. 2001;88(2):165–75.
5. Sharma S, Camci C JN. Review
Management of hepatic metastasis
from colorectal cancers: an update.
J Hepatobiliary Pancreat Surg.
2008;15(6):570–80.
6. Adam R, Laurent A, Azoulay
D, Castaing D BH. Two-stage
hepatectomy: A planned strategy to
treat irresectable liver tumors. Ann
Surg. 2000;232(6):777-85.
7. Weledji EP. Review Centralization
of Liver Cancer Surgery and Impact
on Multidisciplinary Teams Working
on Stage IV Colorectal Cancer. Oncol
Rev. 2017;11(2):331.
8. Adam R, de Gramont A, Figueras J,
Kokudo N, Kunstlinger F, Loyer E,
Poston G, Rougier P, Rubbia-Brandt
L, Sobrero A, Teh C, Tejpar S, Van
Cutsem E, Vauthey JN, Påhlman L
of the E (Expert G on O management
of LiM group. Review Managing
synchronous liver metastases from
colorectal cancer: a multidisciplinary
international consensus. Cancer Treat
Rev. 2015;41(9):729–41.
9. Lius A. A liver adenoma 1886;: Gazz
Clini. 1886;23:225.
10. Langenbuch C. A case of resection
of a left-sided cord lobe of the liver.
Berl Klin Wochenschr. 1888;25:37-39.
11. Cantlie J. On a new arrangement of
the right and left lobes of the liver.
1898;32: J Anat Physiol. 1898;32:4.
12. Keen WW. On resection of the
liver, especially for hepatic tumors.
1892;126:. Bost Med Surg J.
1892;126:405.
13. Wendel W. Beitrage zur chirurgie der
leber. Arch Klin Chir. 1911;95:887.
14. Honjo I AC. Total resection of the right
lobe of the liver: report of a successful
case. J Int Coll Surg. 1955;23:23–8.
15. Couinaud C. Lobes et segments
hepatiques: notes sur archi_tecture
anatomique et chirurgicale du
foie. 1954;62:709-712. Press Méd.
1954;62:709–12.
16. Starzl TE, Iwatsuki S, Van Thiel DH,
Carlton Gartner J, Zitelli BJ, Jeffrey
Malatack J, Schade RR, Shaw Jr BW,
Hakala TR, Thomas Rosenthal J PK.
Evolution of liver transplantation.
1982 Sep;2(5):614S-36S. Hepatology.
1982;2(5):614–36.
17. Starzl TE, Bell RH, Beart RW PC.
Hepatic triseg_mentectomy and other
liver resections. 1975;141(3):429-437.
Surg Gynecol Obs. 1975;141(3):429–37.
18. Hodgson WJ, Poddar PK, Mencer EJ,
Williams J DM, AJ. M. Evaluation of
ultrasonically powered instruments
in the laboratory and in the
clinical setting. 1979;72(2):. Am J
Gastroenterol. 1979;72(2):133–40.
19. Makuuchi M, Thai BL, Takayasu
K, Takayama T, Kosuge T, Gunven
P, Yamazaki S, Hasegawa H OH.
Preoperative portal embolization
to increase the safety of major
hepatectomy for hilar bile duct
carcinoma: a preliminary report.
Surgery. 1990;107(5):521–7.
20. McEntee GP, Nagorney DM. Use of
vascular staplers in major hepatic
resections. Br J Surg. 1991;78(1):40–1.
21. Ballinger, A. B., & Anggiansah
C. Colorectal cancer. BMJ.
2007;335(7622):715–718.
22. Jänne, P. A., & Mayer RJ.
Chemoprevention of colorectal cancer.
N Engl J Med. 2000;342(26):1960–8.
23. Borthwick, L. A., Gardner, A., De
Soyza, A., Mann, D. A., & Fisher
AJ. Transforming Growth Factor-β1
(TGF-β1) Driven Epithelial to
Mesenchymal Transition (EMT) is
Accentuated by Tumour Necrosis
Factor α (TNFα) via Crosstalk
Between the SMAD and NF-κB
Pathways. Cancer Microenviron
Int Cancer Microenviron Soc.
2012;5(1):45–57.
24. Xiong, H., Hong, J., Du, W., Lin,
Y. W., Ren, L. L., Wang, Y. C.,
Su, W. Y., Wang, J. L., Cui, Y.,
Wang, Z. H., & Fang JY. Roles
of STAT3 and ZEB1 proteins in
E-cadherin down-regulation and
human colorectal cancer epithelialmesenchymal
transition. J Biol Chem.
2012;287(8):5819–5832.
25. Stoops, S. L., Pearson, A. S.,
Weaver, C., Waterson, A. G., Days,
E., Farmer, C., Brady, S., Weaver, C.
D., Beauchamp, R. D., & Lindsley
CW. Identification and optimization
of small molecules that restore
E-cadherin expression and reduce
invasion in colorectal carcinoma cells.
ACS Chem Biol. 2011;6(5):452–465.
26. Lawler PR, Lawler J. Molecular basis
for the regulation of angiogenesis
by thrombospondin-1 and -2. Cold
Spring Harb Perspect Med. 2012;2(5).
27. Risau W. Mechanisms of angiogenesis.
Vol. 386, Nature. 1997. p. 671–4.
28. Owen JL, Mohamadzadeh M.
Macrophages and chemokines as
mediators of angiogenesis. Front
Physiol. 2013;4 JUL(July):1–9.
29. Nagahashi M, Ramachandran S,
Rashid OM TK. Lymphangiogenesis:
a new player in cancer progression.
World J Gast roenterol.
2010;16(32):4003-4012.
30. Saad RS, Kordunsky L, Liu YL,
Denning KL, Kandil HA, Silverman
JF. Lymphatic microvessel density as
prognostic marker in colorectal cancer.
Mod Pathol. 2006;19(10):1317–23.
31. Gomes FG, Nedel F, Alves AM,
Nör JE, Tarquinio SBC. Tumor
angiogenesis and lymphangiogenesis:
Tumor/endothelial crosstalk and
cel lular/microenvi ronmental
signaling mechanisms. Life Sci.
2013;92(2):101–7. 32. Rejniak KA. Investigating dynamical
deformations of tumor cells in
circulation: predictions from a
theoretical model. Front Oncol.
2012;2:111.
33. Shin MK, Kim SK, Jung H.
Integration of intra- and extravasation
in one cell-based microfluidic chip for
the study of cancer metastasis. Lab
Chip. 2011;11(22):3880–7.
34. Joyce JA, Pollard JW.
Microenvironmental regulation
of metastasis. Nat Rev Cancer.
2009;9(4):239–52.
35. Samak R IL. [Extraction and
identification of circulating immune
complexes from the serum of cancer
patient by affinity chromatography
followed by high pressure steric
exclusion chromatography.
Demonstration of their effect on the
mitogenesis of normal lymphocytes].
Ann Med Interne. 1982;133(5):362–6.
36. Bird NC, Mangnall D, Majeed
AW. Biology of colorectal liver
metastases: A review. J Surg Oncol.
2006;94(1):68–80.
37. Wang D, Chen M, Tao Z, Du J, Tian
K, Chen Z, et al. Overexpression of
Extracellular Superoxide Dismutase
3 Inhibits Cancer Cell Growth and
Migration in Colorectal Cancer.
Turkish J Gastroenterol Off J
Turkish Soc Gastroenterol. 2024
Jun;35(6):465–74.
38. Garajova I, Balsano R, Tommasi C,
Dalla Valle R, Pedrazzi G, Ravaioli M,
et al. Synchronous and metachronous
colorectal liver metastases: impact of
primary tumor location on patterns
of recurrence and survival after
hepatic resection. Acta Biomed. 2020
Dec;92(1):e2021061.
39. Niekel MC, Bipat S SJ. Diagnostic
imaging of colorectal liver metastases
with CT, MR imaging, FDG PET, and/
or FDG PET/CT: a meta-analysis
of prospective studies including
patients who have not previously
undergone treatment. Radiology.
2010;257(3):674-84.
40. Yoon S, Kim YJ, Jeon JS, Ahn SJ,
Choi SJ. Radiomics and machine
learning analysis of liver magnetic
resonance imaging for prediction and
early detection of tumor response in
colorectal liver metastases. Korean J
Clin Oncol. 2024 May;20(1):27–35.
41. Inna Chen, Torben Lorentzen, Dorte
Linnemann CPN, Bjørn Skjoldbye
BVJ& DN. Seeding after ultrasoundguided
percutaneous biopsy of liver
metastases in patients with colorectal
or breast cancer. Acta Oncol (Madr).
2016;55(5):638–43.
42. Thomas DS, Fourkala EO, Apostolidou
S, Gunu R, Ryan A, Jacobs I, Menon
U, Alderton W, Gentry-Maharaj
A TJ. Evaluation of serum CEA,
CYFRA21-1 and CA125 for the early
detection of colorectal cancer using
longitudinal preclinical samples. Br
J Cancer. 2015;113(2):268–74.
43. Lau H, Man K, Fan ST, Yu WC, Lo
CM WJ. Evaluation of preoperative
hepatic function in patients
with hepatocellular carcinoma
undergoing hepatectomy. Br J Surg.
1997;84(9):1255–9.
44. Cieslak KP, Runge JH, Heger M,
Stoker J, Bennink RJ van GT. Review
New perspectives in the assessment
of future remnant liver. Dig Surg.
2014;31(4–5):255-68.
45. de Graaf W, van Lienden KP, Dinant
S, Roelofs JJ, Busch OR, Gouma DJ,
Bennink RJ van GT. Assessment of
future remnant liver function using
hepatobiliary scintigraphy in patients
undergoing major liver resection. J
Gastrointest Surg. 2010;14(2):369-78.
46. Cieslak KP, Runge JH, Heger M,
Stoker J, Bennink RJ VGT. New
perspectives in the assessment of
future remnant liver. Dig Surg.
2014;31(4–5):255–68.
47. Fong Y, Fortner J, Sun RL, Brennan
MF BL. Clinical score for predicting
recurrence after hepatic sresection for
metastatic colorectal cancer: analysis
of 1001 consecutive cases. Ann Surg.
1999;230(3):309.
48. Nagashima I, Takada T, Okinaga
K NH. A scoring system for the
assessment of the risk of mortality
after partial hepatectomy in patients
with chronic liver dysfunction.
J Hepatobiliary Pancreat Surg.
2005;12(1):44–8.
49. Schroeder RA, Marroquin CE, Bute
BP, Khuri S, Henderson WG KP.
Predictive indices of morbidity and
mortality after liver resection. Ann
Surg. 2006;243(3):373.
50. Kamath PS KW. The model for
end‐stage liver disease (MELD).
Hepatology. 2007;45(3):797–805.
51. Giuliante F, Viganò L, De Rose
AM, Mirza DF, Lapointe R, Kaiser
G, et al. Liver-First Approach for
Synchronous Colorectal Metastases:
Analysis of 7360 Patients from the
LiverMetSurvey Registry. Ann Surg
Oncol. 2021 Dec;28(13):8198–208.
52. Chow FC-L, Chok KS-H. Colorectal
liver metastases: An update on
multidisciplinary approach. World J
Hepatol. 2019 Feb;11(2):150–72.
53. Kanas GP, Taylor A, Primrose JN,
Langeberg WJ, Kelsh MA, Mowat
FS, Alexander DD, Choti MA PG.
Survival after liver resection in
metastatic colorectal cancer: review
and meta-analysis of prognostic
factors. Clin Epidemiol. 2012;4:283.
54. Procopio F, Torzilli G, Franchi E,
Cimino M, Viganò L, Donadon M,
et al. Ultrasound-guided anatomical
liver resection using a compression
technique combined with indocyanine
green fluorescence imaging. HPB.
2020 Jun 1;23.
55. Sasson AR, Sigurdson ER. Surgical
treatment of liver metastases. Semin
Oncol. 2002;29(2):107–18.
56. Altendorf-Hofmann A, Scheele J. A
critical review of the major indicators
of prognosis after resection of
hepatic metastases from colorectal
carcinoma. Surg Oncol Clin N Am.
2003;12(1):165–92.
57. Lam VW, Laurence JM, Johnston
E, Hollands MJ, Pleass HC RA.
Review A systematic review of twostage
hepatectomy in patients with
initially unresectable colorectal liver
metastases. HPB. 2013;15(7):483–91.
58. Moris D, Ronnekleiv-Kelly S,
Kostakis ID, Tsilimigras DI, Beal
EW, Papalampros A, Dimitroulis
D, Felekouras E PT. Operative
Results and Oncologic Outcomes
of Associating Liver Partition and
Portal Vein Ligation for Staged
Hepatectomy (ALPPS) Versus Two-
Stage Hepatectomy (TSH) in Patients
with Unresectable Colorectal Liver
Metastases: A Systematic Review
and Meta-Anal. World J Surg.
2018;42(3):806–15.
59. Sandström P, Røsok BI, Sparrelid E,
Larsen PN, Larsson AL, Lindell G,
Schultz NA, Bjørnbeth BA, Isaksson
B, Rizell M BB. ALPPS Improves
Resectability Compared With
Conventional Two-stage Hepatectomy
in Patients With Advanced
Colorectal Liver Metastasis: Results
From a Scandinavian Multicenter
Randomized Controlled Trial (LIGRO
Trial). Ann Surg. 2018;267(5):833–40.
60. Mise Y, Aloia TA, Brudvik KW,
Schwarz L, Vauthey JN CC.
Parenchymal-sparing Hepatectomy in
Colorectal Liver Metastasis Improves
Salvageability and Survival. Ann
Surg. 2016;263(1):146–52.
61. Petre EN SC. Thermal Ablation in
the Management of Colorectal Cancer
Patients with Oligometastatic Liver
Disease. Visc Med. 2017;33(1):62–8.
62. Correa-Gallego C, Fong Y, Gonen M,
D’Angelica MI, Allen PJ, DeMatteo
RP, Jarnagin WR KT. A retrospective
comparison of microwave ablation vs.
radiofrequency ablation for colorectal
cancer hepatic metastases. Ann Surg
Oncol. 2014;21(13):4278-83.
63. McEachron KR, Ankeny JS, Robbins
A, Altman AM, Marmor S, D’Souza
D, et al. Surgical microwave ablation of otherwise non-resectable colorectal
cancer liver metastases: Expanding
opportunities for long term survival.
Surg Oncol. 2021 Mar;36:61–4.
64. Hitpass L, Distelmaier M, Neumann
UP, Schöning W, Isfort P, Keil S,
et al. Recurrent Colorectal Liver
Metastases in the Liver Remnant
After Major Liver Surgery-IRE as
a Salvage Local Treatment When
Resection and Thermal Ablation are
Unsuitable. Cardiovasc Intervent
Radiol. 2022 Feb;45(2):182–9.
65. Xing M, Kooby DA, El-Rayes
BF, Kokabi N, Camacho JC KH.
Locoregional therapies for metastatic
colorectal carcinoma to the liver--an
evidence-based review. J Surg Oncol.
2014;110(2):182-96.
66. Chang AE, Schneider PD, Sugarbaker
PH, Simpson C, Culnane M, Steinberg
SM. A prospective randomized trial of
regional versus systemic continuous
5-fluorodeoxyuridine chemotherapy
in the treatment of colorectal
liver metastases. Ann Surg. 1987
Dec;206(6):685–93.
67. Fiorentini G, Rossi S, Dentico P,
Meucci F, Bonechi F, Bernardeschi
P, et al. Oxaliplatin hepatic arterial
infusion chemotherapy for hepatic
metastases from colorectal cancer: a
phase I-II clinical study. Anticancer
Res. 2004;24(3b):2093–6.
68. Malka D, Verret B, Faron M,
Guimbaud R, Caramella C, Edeline
J, et al. Hepatic arterial oxaliplatin
plus intravenous 5-fluorouracil and
cetuximab for first-line treatment
of colorectal liver metastases: A
multicenter phase II trial. Eur J
Cancer. 2023 Dec;195:113400.
69. Kemeny NE, Jarnagin WR, Capanu
M, Fong Y, Gewirtz AN, DeMatteo
RP, et al. Randomized Phase II Trial
of Adjuvant Hepatic Arterial Infusion
and Systemic Chemotherapy With
or Without Bevacizumab in Patients
With Resected Hepatic Metastases
From Colorectal Cancer. J Clin Oncol
[Internet]. 2010 Dec 28;29(7):884–
9. Available from: https://doi.
org/10.1200/JCO.2010.32.5977
70. Boilève A, De Cuyper A, Larive A,
Mahjoubi L, Najdawi M, Tazdait
M, et al. Hepatic arterial infusion of
oxaliplatin plus systemic chemotherapy
and targeted therapy for unresectable
colorectal liver metastases. Eur J
Cancer [Internet]. 2020;138:89–
98. Available from: https://www.
sciencedirect.com/science/article/pii/
S0959804920304226
71. Boige V, Malka D, Elias D, Castaing
M, De Baere T, Goere D, et al. Hepatic
arterial infusion of oxaliplatin and
intravenous LV5FU2 in unresectable
liver metastases from colorectal
cancer after systemic chemotherapy
failure. Ann Surg Oncol. 2008
Jan;15(1):219–26.
72. Ducreux M, Ychou M, Laplanche A,
Gamelin E, Lasser P, Husseini F, et al.
Hepatic arterial oxaliplatin infusion
plus intravenous chemotherapy in
colorectal cancer with inoperable
hepatic metastases: a trial of
the gastrointestinal group of the
Federation Nationale des Centres de
Lutte Contre le Cancer. J Clin Oncol
Off J Am Soc Clin Oncol. 2005
Aug;23(22):4881–7.
73. Chen Y-C, Huang C-W, Li C-C, Chang
T-K, Su W-C, Chen P-J, et al. Efficacy
of transarterial chemoembolization
with drug-eluting beads combined
with systemic chemotherapy and
targeted therapy in colorectal cancer
liver metastasis. World J Surg Oncol.
2023 Dec;21(1):378.
74. Hendlisz A, Van den Eynde M,
Peeters M, Maleux G, Lambert
B, Vannoote J, De Keukeleire K,
Verslype C, Defreyne L, Van Cutsem
E, Delatte P, Delaunoit T, Personeni
N, Paesmans M, Van Laethem JL FP.
Phase III trial comparing protracted
intravenous fluorouracil infusion
alone or with yttrium-90 resin
microspheres radioembolization for
liver-limited metastatic colorectal
cancer refractory to standard
chemotherapy. 2010 Aug 10; 28(23):
J Clin Oncol. 2010;28(23):3687-94.
75. Al-Sharif E, Simoneau E HM. Portal
vein embolization effect on colorectal
cancer liver metastasis progression:
Lessons learned. 2015 Oct 10; 6(5):
World J Clin Oncol. 2015;6(5):142-6.
76. Yang T, Chen Q, Kuang L, Fu Z, Wang
Y, Chen Y, et al. Effectiveness and
safety of ultrasound-guided highintensity
focused ultrasound ablation
for the treatment of colorectal cancer
liver metastases. Int J Hyperth Off J
Eur Soc Hyperthermic Oncol North
Am Hyperth Gr. 2022;39(1):829–34.
77. Tang F, Zhong Q, Ni T, Xue Y, Wu
J, Deng R, et al. High-intensity
focused ultrasound ablation
combined with systemic therapy
for unresectable colorectal cancer
liver metastasis: A propensity scorematched
analysis. Cancer Med. 2023
Dec;12(24):21985–95.
78. Dueland S, Syversveen T, Solheim
JM, Solberg S, Grut H, Bjørnbeth
BA, et al. Survival Following Liver
Transplantation for Patients With
Nonresectable Liver-only Colorectal
Metastases. Ann Surg. 2020
Feb;271(2):212–8.
79. Pan CC, Kavanagh BD, Dawson
LA, Li XA, Das SK, Miften M, et
al. Radiation-associated liver injury.
Int J Radiat Oncol Biol Phys. 2010
Mar;76(3 Suppl):S94-100.
80. Rosu M, Dawson LA, Balter JM,
McShan DL, Lawrence TS, Ten
Haken RK. Alterations in normal
liver doses due to organ motion.
Int J Radiat Oncol Biol Phys. 2003
Dec;57(5):1472–9.
81. Lam VWT, Spiro C, Laurence JM,
Johnston E, Hollands MJ, Pleass HCC,
et al. A systematic review of clinical
response and survival outcomes of
downsizing systemic chemotherapy
and rescue liver surgery in patients
with initially unresectable colorectal
liver metastases. Ann Surg Oncol.
2012;19(4):1292–301.
82. Kanat O. Current treatment options
for patients with initially unresectable
isolated colorectal liver metastases.
World J Clin Oncol. 2016;7(1):9-14.
83. Falcone A, Ricci S, Brunetti I,
Pfanner E, Allegrini G, Barbara C,
Crinò L, Benedetti G, Evangelista
W, Fanchini L, Cortesi E, Picone
V, Vitello S, Chiara S, Granetto C,
Porcile G, Fioretto L, Orlandini C,
Andreuccetti M, Masi G GONO. Phase
III trial of infusional fluorouracil,
leucovorin, oxaliplatin, and irinotecan
(FOLFOXIRI) compared with
infusional fluorouracil, leucovorin,
and irinotecan (FOLFIRI) as firstline
treatment for metastatic colorectal
cancer: the Gruppo Oncologico Nor. J
Clin Oncol. 2007;25(13):1670-6.
84. Van Cutsem E, Cervantes A, Adam R,
Sobrero A, Van Krieken JH, Aderka
D, et al. ESMO consensus guidelines
for the management of patients with
metastatic colorectal cancer. Ann
Oncol. 2016;27(8):1386–422.
85. Turan N, Benekli M, Koca D, Ustaalioglu
BO, Dane F, Ozdemir N, et al. Adjuvant
systemic chemotherapy with or without
bevacizumab in patients with resected
liver metastases from colorectal cancer.
Oncol. 2012;84(1):14–21.
86. Van Kessel CS, Buckens CFM, Van
Den Bosch MAAJ, Van Leeuwen MS,
Van Hillegersberg R, Verkooijen HM.
Preoperative imaging of colorectal
liver metastases after neoadjuvant
chemotherapy: A meta-analysis. Ann
Surg Oncol. 2012;19(9):2805–13.
87. Ntourakis D, Memeo R, Soler L,
Marescaux J, Mutter D, Pessaux P.
Augmented Reality Guidance for the
Resection of Missing Colorectal Liver
Metastases: An Initial Experience.
World J Surg. 2016;40(2):419–26.
88. Zendel A, Lahat E, Dreznik Y, Zakai
BB, Eshkenazy R, Ariche A. ‘Vanishing
liver metastases’-A real challenge for
liver surgeons. Hepatobiliary Surg
Nutr. 2014;3(5):295–302.
)